keyword
MENU ▼
Read by QxMD icon Read
search

Meningococcal vaccinations

keyword
https://www.readbyqxmd.com/read/27912986/a-phase-iii-observer-blind-randomized-controlled-study-to-evaluate-the-immune-response-and-the-correlation-with-nasopharyngeal-carriage-after-immunization-of-university-students-with-a-quadrivalent-meningococcal-acwy-glycoconjugate-or-serogroup-b-meningococcal
#1
Robert C Read, Peter Dull, Xilian Bai, Kate Nolan, Jamie Findlow, Rohit Bazaz, Annett Kleinschmidt, Maggie McCarthy, Huajun Wang, Daniela Toneatto, Ray Borrow
BACKGROUND: University students have high rates of pharyngeal carriage of Neisseria meningitidis. Interruption of carriage acquisition is an important mechanism of vaccines for inducing herd protection. 4CMenB and MenACWY-CRM vaccines have been shown to be immunogenic against meningococcal serogroups B and ACWY respectively in younger age groups, and also to elicit a modest impact on meningococcal carriage in vaccinated students. However, vaccine responses in university students and the impact of serum bactericidal antibody (SBA) titers on meningococcal carriage are undetermined...
November 29, 2016: Vaccine
https://www.readbyqxmd.com/read/27907129/meningococcal-carriage-in-military-recruits-and-university-students-during-the-pre-menb-vaccination-era-in-greece-2014-2015
#2
Kyriaki Tryfinopoulou, Konstantinos Kesanopoulos, Athanasia Xirogianni, Nektarios Marmaras, Anastasia Papandreou, Vassiliki Papaevangelou, Maria Tsolia, Aftab Jasir, Georgina Tzanakaki
PURPOSE: The aim of the study was to estimate the meningococcal carriage rate and to identify the genotypic characteristics of the strains isolated from healthy military recruits and university students in order to provide data that might increase our understanding on the epidemiology of meningococcus and obtain information which helps to evaluate the potential effects on control programs such as vaccination. METHODS: A total of 1420 oropharyngeal single swab samples were collected from military recruits and university students on voluntary basis, aged 18-26 years...
2016: PloS One
https://www.readbyqxmd.com/read/27904879/the-establishment-and-diversification-of-epidemic-associated-serogroup-w-meningococcus-in-the-african-meningitis-belt-1994-to-2012
#3
Adam C Retchless, Fang Hu, Abdoul-Salam Ouédraogo, Seydou Diarra, Kristen Knipe, Mili Sheth, Lori A Rowe, Lassana Sangaré, Absetou Ky Ba, Soumeya Ouangraoua, Dhwani Batra, Ryan T Novak, Rasmata Ouédraogo Traoré, Xin Wang
Epidemics of invasive meningococcal disease (IMD) caused by meningococcal serogroup A have been eliminated from the sub-Saharan African so-called "meningitis belt" by the meningococcal A conjugate vaccine (MACV), and yet, other serogroups continue to cause epidemics. Neisseria meningitidis serogroup W remains a major cause of disease in the region, with most isolates belonging to clonal complex 11 (CC11). Here, the genetic variation within and between epidemic-associated strains was assessed by sequencing the genomes of 92 N...
November 2016: MSphere
https://www.readbyqxmd.com/read/27902653/meningococcal-disease-in-children-in-argentina-a-three-year-active-sentinel-hospital-surveillance-study
#4
Ángela Gentile, Julia Bakir, María Rosa Agosti, Gabriela Ensinck, Hector Abate, Andrea Gajo Gane, Alejandro Santillán Iturres, Adriana Efron, Mabel Regueira, Ricardo Rüttimann
BACKGROUND: Meningococcal disease (MD) is a medical emergency and a serious public health problem. As new meningococcal vaccines become available, MD surveillance is crucial to provide baseline epidemiologic data before implementing preventive measures. We estimated MD incidence and epidemiology in Argentina using hospital-based surveillance. METHODS: 3-year prospective active surveillance in patients ≤15 years of age conducted at 6 pediatric hospital sentinel units (March 2012-February 2015)...
November 28, 2016: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/27884478/vaccine-provision-delivering-sustained-widespread-use
#5
Scott Preiss, Nathalie Garçon, Anthony L Cunningham, Richard Strugnell, Leonard R Friedland
The administration of a vaccine to a recipient is the final step in a development and production process that may have begun several decades earlier. Here we describe the scale and complexity of the processes that brings a candidate vaccine through clinical development to the recipient. These challenges include ensuring vaccine quality (between 100 and 500 different Quality Control tests are performed during production to continually assess safety, potency and purity); making decisions about optimal vaccine presentation (pre-filled syringes versus multi-dose vials) that affect capacity and supply; and the importance of maintaining the vaccine cold chain (most vaccines have stringent storage temperature requirements necessary to maintain activity and potency)...
November 21, 2016: Vaccine
https://www.readbyqxmd.com/read/27881489/kinetics-of-meningococcal-serogroup-c-specific-functional-antibody-levels-up-to-15-years-after-a-single-immunization-with-a-meningococcal-serogroup-c-conjugate-vaccine-during-adolescence
#6
Susanne P Stoof, Mariëtte B van Ravenhorst, Debbie M van Rooijen, Richarda M de Voer, Fiona R M van der Klis, Greet J Boland, Elisabeth A M Sanders, Guy A M Berbers, Peter F Teunis
BACKGROUND: Adolescent vaccination is now considered the key factor to offer direct protection against meningococcal disease but also to reduce carriage and transmission and in this way establish herd protection. This study estimated age-dependent patterns in functional meningococcal serogroup C (MenC) antibody kinetics after primary MenC conjugate (MenCC) vaccination in adolescents. METHODS: Serum samples (n=1676) were drawn between 2006-2011 from individuals aged 9-18 years at time of primary MenCC vaccination in 2002...
November 23, 2016: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/27876200/improving-adolescent-hpv-vaccination-in-a-randomized-controlled-cluster-trial-using-the-4-pillars%C3%A2-practice-transformation-program
#7
Richard K Zimmerman, Krissy K Moehling, Chyongchiou J Lin, Song Zhang, Jonathan M Raviotta, Evelyn C Reis, Sharon G Humiston, Mary Patricia Nowalk
OBJECTIVE: Uptake of meningococcal vaccine (MCV) and tetanus, diphtheria and pertussis (Tdap) vaccine among adolescents has approached Healthy People 2020 goals, but human papillomavirus (HPV) vaccination has not. This study evaluated an intervention using the 4 Pillars™ Practice Transformation Program to increase HPV, MCV and Tdap uptake among adolescents in primary care practices. METHODS: Practices with at least 50 patients 11-17years old with estimated vaccination rates less than national goals, were assigned to intervention (n=11) and control (n=11) groups in a randomized controlled cluster trial; 9 intervention and 11 control sites completed the study...
November 18, 2016: Vaccine
https://www.readbyqxmd.com/read/27869440/immunology-update-new-vaccines
#8
S Paul Starr
A new 9-valent human papillomavirus (HPV) vaccine is effective against more cancer-causing HPV types than previous vaccines. HPV vaccine series started with previous vaccines can be completed with the 9-valent vaccine. Two new influenza vaccines are available for adults 65 years and older: a high-dose vaccine and an enhanced adjuvant vaccine. These elicit stronger antibody responses than standard-dose vaccines. Current guidelines specify no preference for the new versus standard-dose vaccines. Two new group B meningococcal vaccines are intended for use during outbreaks and for patients with asplenia, complement deficiencies, frequent occupational meningococcus exposure, or for patients who desire protection from type B meningococcus...
November 2016: FP Essentials
https://www.readbyqxmd.com/read/27864913/human-secretory-igm-antibodies-activate-human-complement-and-offer-protection-at-mucosal-surface
#9
Terje E Michaelsen, Sidsel Emilsen, Randi H Sandin, Beathe Kiland Granerud, Diane Bratlie, Oistein Ihle, Inger Sandlie
IgM molecules circulate in serum as large polymers, mainly pentamers, which can be transported by the poly-Ig receptor (pIgR) across epithelial cells to mucosal surfaces and released as secretory IgM (SIgM). The mucosal SIgM molecules have non-covalently attached secretory component (SC), which is the extracellular part of pIgR which is cleaved from the epithelial cell membrane. Serum IgM antibodies do not contain SC, and have previously been shown to make a conformational change from "a star" to a "staple" conformation upon reaction with antigens on a cell surface, enabling them to activate complement...
November 16, 2016: Scandinavian Journal of Immunology
https://www.readbyqxmd.com/read/27861618/meningococcal-carriage-among-adolescents-after-mass-meningococcal-c-conjugate-vaccination-campaigns-in-salvador-brazil
#10
Amélia Maria Pithon Borges Nunes, Guilherme Sousa Ribeiro, Ítalo Eustáquio Ferreira, Ana Rafaela Silva Simões Moura, Ridalva Dias Martins Felzemburgh, Ana Paula Silva de Lemos, Mitermayer Galvão Reis, José Cassio de Moraes, Leila Carvalho Campos
Neisseria meningitidis is a commensal bacterium of the human nasopharynx. In rare cases, it penetrates the mucosa, entering the blood stream and causing various forms of disease. Meningococcal conjugate vaccines can prevent invasive disease not only by direct effect in vaccinated individuals but also by herd protection, preventing acquisition of carriage, which interrupts transmission and leads to protection of unvaccinated persons. In 2010 in Salvador, Brazil, an outbreak of group C meningococcal disease led to a mass meningococcal serogroup C conjugate vaccination drive, targeting those <5 and 10-24 years of age...
2016: PloS One
https://www.readbyqxmd.com/read/27849512/a-fatal-case-of-invasive-infection-caused-by-w135-neisseria-meningitidis-in-a-vaccinated-french-soldier
#11
Sandrine Duron, Christophe Martinaud, David Lacassagne, Jean-Louis Koeck
We report on the case of fatal "purpura fulminans" caused by Neisseria meningitidis W135 that occurred in a young French soldier vaccinated a few months earlier with the tetravalent conjugate vaccine ACYW135. Biological investigations revealed adequate titers of postvaccination antibodies against serogroups A, C, and W135 and led to the post-mortem diagnosis of a complete C7 complement deficiency. Late complement component deficiency is a well-known risk factor of meningococcal diseases, but usually exposes to recurrent mild infections, whereas severe invasive meningococcal diseases are more likely to occur among properdin-deficient patients...
November 2016: Military Medicine
https://www.readbyqxmd.com/read/27847367/serum-bactericidal-antibody-responses-of-adults-immunized-with-the-menb-4c-vaccine-against-genetically-diverse-serogroup-b-meningococci
#12
Serena Giuntini, Eduardo Lujan, Malick M Gibani, Christina Dold, Christine S Rollier, Andrew J Pollard, Dan M Granoff
BACKGROUND: MenB-4C is a meningococcal vaccine for prevention of serogroup B disease. The vaccine contains Factor H binding protein (FHbp) and three other antigens that can elicit serum bactericidal activity (SBA). For vaccine licensure, efficacy was inferred from SBA responses against three indicator strains. The relation between the results and broad protection against circulating genetically diverse strains is not known. METHODS: 20 adults were immunized with two doses of MenB-4C given 1 to 2 months apart...
November 9, 2016: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/27846061/neisseria-meningitidis-serogroup-b-vaccine-bivalent-rlp2086-induces-broad-serum-bactericidal-activity-against-diverse-invasive-disease-strains-including-outbreak-strains
#13
Shannon L Harris, Robert G K Donald, Julio Cesar Hawkins, Cuiwen Tan, Robert O'Neill, Lisa K McNeil, John L Perez, Annaliesa S Anderson, Kathrin U Jansen, Thomas R Jones
BACKGROUND: Bivalent rLP2086 (Trumenba®), 1 of 2 meningococcal serogroup B (MnB) vaccines recently approved in the United States for prevention of MnB disease in individuals aged 10-25 years, is composed of 2 lipidated factor H binding proteins (fHBPs) from subfamilies A and B. This study evaluated the breadth of MnB strain coverage elicited by bivalent rLP2086 measured with serum bactericidal assays using human complement (hSBAs). METHODS: hSBA responses to diverse MnB clinical strains circulating in the United States and Europe (n=23), as well as recent US university outbreak strains (n=4), were evaluated...
November 11, 2016: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/27832151/nationwide-trends-in-bacterial-meningitis-before-the-introduction-of-13-valent-pneumococcal-conjugate-vaccine-burkina-faso-2011-2013
#14
Dinanibè Kambiré, Heidi M Soeters, Rasmata Ouédraogo-Traoré, Isaïe Medah, Lassana Sangare, Issaka Yaméogo, Guetawendé Sawadogo, Abdoul-Salam Ouédraogo, Soumeya Hema-Ouangraoua, Lesley McGee, Velusamy Srinivasan, Flavien Aké, Malika Congo-Ouédraogo, Soufian Sanou, Absatou Ky Ba, Ryan T Novak, Chris Van Beneden
BACKGROUND: Following introduction of Haemophilus influenzae type b vaccine in 2006 and serogroup A meningococcal conjugate vaccine in 2010, Streptococcus pneumoniae (Sp) became the leading cause of bacterial meningitis in Burkina Faso. We describe bacterial meningitis epidemiology, focusing on pneumococcal meningitis, before 13-valent pneumococcal conjugate vaccine (PCV13) introduction in the pediatric routine immunization program in October 2013. METHODS: Nationwide population-based meningitis surveillance collects case-level demographic and clinical information and cerebrospinal fluid (CSF) laboratory results...
2016: PloS One
https://www.readbyqxmd.com/read/27820969/the-global-meningococcal-initiative-global-epidemiology-the-impact-of-vaccines-on-meningococcal-disease-and-the-importance-of-herd-protection
#15
Ray Borrow, Pedro Alarcón, Josefina Carlos, Dominique A Caugant, Hannah Christensen, Roberto Debbag, Philippe De Wals, Gabriela Echániz-Aviles, Jamie Findlow, Chris Head, Daphne Holt, Hajime Kamiya, Samir K Saha, Sergey Sidorenko, Muhamed-Kheir Taha, Caroline Trotter, Julio A Vázquez Moreno, Anne von Gottberg, Marco A P Sáfadi
The 2015 Global Meningococcal Initiative (GMI) meeting discussed the global importance of meningococcal disease (MD) and its continually changing epidemiology. Areas covered: Although recent vaccination programs have been successful in reducing incidence in many countries (e.g. Neisseria meningitidis serogroup [Men]C in Brazil, MenA in the African meningitis belt), new clones have emerged, causing outbreaks (e.g. MenW in South America, MenC in Nigeria and Niger). The importance of herd protection was highlighted, emphasizing the need for high vaccination uptake among those with the highest carriage rates, as was the need for boosters to maintain individual and herd protection following decline of immune response after primary immunization...
November 22, 2016: Expert Review of Vaccines
https://www.readbyqxmd.com/read/27817957/long-term-persistence-of-protective-antibodies-in-dutch-adolescents-following-a-meningococcal-serogroup-c-tetanus-booster-vaccination
#16
Mariëtte B van Ravenhorst, Axel Bonacic Marinovic, Fiona R M van der Klis, Debbie M van Rooijen, Marjan van Maurik, Susanne P Stoof, Elisabeth A M Sanders, Guy A M Berbers
INTRODUCTION: Due to waning immunity, infant vaccination with meningococcal serogroup C conjugated (MenCC) vaccines is insufficient to maintain long-term individual protection. Adolescent booster vaccination is thought to offer direct protection against invasive meningococcal disease (IMD) but also to reduce meningococcal carriage and transmission and in this way establish herd protection in the population. Previously, we studied antibody levels after adolescent MenCC booster vaccination...
December 7, 2016: Vaccine
https://www.readbyqxmd.com/read/27814682/prevalence-and-epidemiology-of-meningococcal-carriage-in-southern-ethiopia-prior-to-implementation-of-menafrivac-a-conjugate-vaccine
#17
Guro K Bårnes, Paul A Kristiansen, Demissew Beyene, Bereket Workalemahu, Paulos Fissiha, Behailu Merdekios, Jon Bohlin, Marie-Pierre Préziosi, Abraham Aseffa, Dominique A Caugant
BACKGROUND: Neisseria meningitidis colonizes humans and transmits mainly by asymptomatic carriage. We sought to determine the prevalence and epidemiology of meningococcal carriage in Ethiopia prior to the introduction of MenAfriVac, a serogroup A meningococcal conjugate vaccine. METHODS: A cross-sectional meningococcal carriage study was conducted in Arba Minch, southern Ethiopia. A total of 7479 oropharyngeal samples were collected from 1 to 29 year old volunteers, between March and October, 2014...
November 4, 2016: BMC Infectious Diseases
https://www.readbyqxmd.com/read/27811836/recommendations-for-use-of-meningococcal-conjugate-vaccines-in-hiv-infected-persons-advisory-committee-on-immunization-practices-2016
#18
Jessica R MacNeil, Lorry G Rubin, Monica Patton, Ismael R Ortega-Sanchez, Stacey W Martin
At its June 2016 meeting, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of meningococcal conjugate vaccine (serogroups A, C, W, and Y; including MenACWY-D [Menactra, Sanofi Pasteur] or MenACWY-CRM [Menveo, GlaxoSmithKline]) for persons aged ≥2 months with human immunodeficiency virus (HIV) infection. ACIP has previously recommended routine vaccination of persons aged ≥2 months who have certain medical conditions that increase risk for meningococcal disease (1), including persons who have persistent (e...
November 4, 2016: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/27808594/immunogenicity-and-safety-among-laboratory-workers-vaccinated-with-bexsero%C3%A2-vaccine
#19
Eva Hong, Aude Terrade, Muhamed-Kheir Taha
Neisseria meningitidis serogroup B is the most prevalent cause of invasive meningococcal disease in Europe and members of laboratories working on meningococci are at risk due to frequent handling. Recommendation for anti-meningococcal vaccination among these workers has been recently updated upon the licensure in Europe of Bexsero® vaccine. We tested the immunogenicity and safety of this vaccine among adults laboratory staff using the recommended schedule of two doses at 5 weeks interval. The vaccine was well tolerated in spite of frequent local side effects and all participants reported at least one side effect after each dose...
November 3, 2016: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/27799502/refusal-of-recommended-travel-related-vaccines-among-u-s-international-travellers-in-global-travepinet
#20
Sara M Lammert, Sowmya R Rao, Emily S Jentes, Jessica K Fairley, Stefanie Erskine, Allison T Walker, Stefan H Hagmann, Mark J Sotir, Edward T Ryan, Regina C LaRocque
BACKGROUND: International travellers are at risk of travel-related, vaccine-preventable diseases. More data are needed on the proportion of travellers who refuse vaccines during a pre-travel health consultation and their reasons for refusing vaccines. METHODS: We analyzed data on travellers seen for a pre-travel health consultation from July 2012 through June 2014 in the Global TravEpiNet (GTEN) consortium. Providers were required to indicate one of three reasons for a traveller refusing a recommended vaccine: (1) cost concerns, (2) safety concerns or (3) not concerned with the illness...
July 2016: Journal of Travel Medicine
keyword
keyword
106661
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"